Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are Japanese patients and who personally provide written agreement to take part in this clinical trial
- People who have been diagnosed with a type of blood cancer called AML (Acute Myeloid Leukaemia), as defined by the World Health Organization's 2022 guidelines, but not a specific subtype called acute promyelocytic leukaemia with a particular genetic change (t(15;17))
- People whose AML has come back after treatment or has not responded to treatment, whether or not a bone marrow or stem cell transplant from a donor has previously been carried out
- People whose AML has been confirmed, through central laboratory testing, to have a specific genetic change called an IDH1 mutation, detected after the cancer returned or stopped responding to treatment
Who may not be able to join:
- People who have a different genetic change called an IDH2 mutation, or who have previously been treated with a medicine that targets IDH2
- People who have had serious problems tolerating medicines that target IDH1
- People who the trial doctor or their team considers to be unsuitable for the trial for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yumi Ikezaki, Kissei Pharmaceutical Co., Ltd.
Phone: Email only
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of adverse events and adverse drug reactions
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.